Post-market evidence
Evidence obligations do not end at approval. Neither does our involvement.
Overview
Evidence obligations do not end at approval
Post-market commitments, safety surveillance and continued evidence generation are treated as a planned programme, not a compliance afterthought.
Surveillance
- Post-market clinical follow-up
- Safety signal monitoring
- Adverse event analysis
- Registry-based surveillance
Evidence
- Real-world effectiveness
- Long-term outcomes
- Comparative post-market studies
- Health economics updates
Reporting
- Regulatory post-market reports
- Periodic safety updates
- Payer & HTA re-submission support
- Label update evidence
Plan post-market evidence.
Build the commitment into the launch plan, not after it.